PharmaShots Weekly Snapshot (Dec 30, 2019-Jan 03, 2020)
1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106 Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals,
[Read More...]
Acceleron
Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases
Shots: Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized
[Read More...]
PharmaShots Weekly Snapshot (September 16– 20, 2019)
1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement,
[Read More...]
Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy
Shots: The P-II clinical study involves assessing ACE-083 in FSHD patient with muscle weakness in the biceps brachii, the tibialis anterior, and a
[Read More...]
Celgene and Acceleron Report FDA’s Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia
Shots: The BLA acceptance follows safety and efficacy data from two P-III MEDALIST and BELIEVE study result assessing Luspatercept vs PBO to treat
[Read More...]
Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to the US FDA for Luspatercept
Shots: The BLA submission is based on P-III MEDALIST & BELIEVE studies. The P-III MEDALIST study involves assessing of luspatercept (1.0 mg/kg) vs
[Read More...]
Acceleron’s ACE-083 Receives FDA’s ODD for Charcot Marie Tooth Disease (CMT)
Shots: The ODD designation follows two P-II studies assessing ACE-083 (Myostatin+ muscle agent) in patients with CMT and facioscapulohumeral muscular dystrophy (FSHD) The
[Read More...]